Baudax Bio (BXRX) Osake Kurssi

Baudax Bio Inc is primarily active in the pharmaceutical industry.

The main competitors of Baudax Bio Inc in the market include other pharmaceutical companies such as Pfizer, Johnson & Johnson, and Amgen.

Baudax Bio Inc is a pharmaceutical company specializing in developing and commercializing innovative therapeutics for acute care settings. Founded in 2019, the company aims to address unmet medical needs and improve patient outcomes. Baudax Bio focuses on pain management and has developed multiple non-opioid products designed to provide effective analgesia while minimizing side effects. By leveraging its experienced team and strategic partnerships, Baudax Bio Inc continues to advance its pipeline and expand its product portfolio. With a strong commitment to medical innovation, the company aims to improve patient quality of life and revolutionize pain management in acute care settings.

Baudax Bio Inc has achieved significant milestones in its journey. The company successfully completed its initial public offering (IPO) in April 2019, raising approximately $20 million in gross proceeds. In November 2019, Baudax Bio received FDA approval for ANJESO™ (meloxicam) injection, a non-opioid, once-daily analgesic for the management of moderate to severe pain. This milestone marked a major breakthrough in the company's mission to provide innovative pain management solutions. Baudax Bio continues to expand its product portfolio and aims to address unmet medical needs through research and development initiatives.

Baudax Bio Inc is primarily present in the United States.

Baudax Bio Inc is a pharmaceutical company that focuses on developing and commercializing innovative products to address acute care needs. With a mission to improve patient outcomes and enhance healthcare practices, Baudax Bio Inc prioritizes integrity, collaboration, and innovation. The company's corporate philosophy revolves around delivering value to patients, healthcare providers, and stakeholders while maintaining strong ethical standards. By leveraging scientific expertise and cutting-edge technology, Baudax Bio Inc strives to bring forth novel therapies and treatments to enhance patient care in acute care settings and contribute to long-term growth in the healthcare sector.

6 analyytikkoa arvioi tällä hetkellä Baudax Bio-osaketta: 0 suosittaa ostoa, 3 pitoa ja 3 myyntiä. Vuodelle 2026 analyytikot odottavat Baudax Bio-yhtiöltä 33,66 M USD liikevaihtoa ja −0,99 USD osakekohtaista tulosta.

Baudax Bio Analyytikkojen kursstavoitteet 2026

Baudax Bio-osake (BXRX) on listattuna 1 pörssissä, muun muassa: NASDAQ (BXRX).

Baudax Bio Inc. is a biopharmaceutical company based in Malvern, Pennsylvania, focused on the development of innovative pain relief products. The company has been in the market since 2019 and has quickly established itself as a key player. Baudax Bio Inc.'s business model is based on the development and commercialization of pain relief products. The company has a wide range of products in its portfolio, divided into various categories. The first category of Baudax Bio Inc. includes products for pain relief after surgical procedures. The company has developed a novel method to reduce pain after surgery. The product is called ANJESO® and was approved by the FDA (Food and Drug Administration) in February 2020. ANJESO® is a nonsteroidal anti-inflammatory drug (NSAID) administered intravenously. The second category of Baudax Bio Inc. includes products for pain relief in acute pain. The company has introduced a new product called BELBUCA®, which was approved by the FDA in November 2016. BELBUCA® is a transmucosal medication used to treat pain caused by cancer or other conditions. The third category of Baudax Bio Inc. includes the development of products based on opioids. The company has launched a product called XYLOX™, which was approved by the FDA in March 2021. XYLOX™ is an opioid used for pain relief in patients suffering from moderate to severe pain. Baudax Bio Inc.'s business model is based on developing innovative pain relief products that meet the needs of doctors, patients, and hospitals. The company works intensively to meet the needs of its customers, emphasizing the highest quality, safety, and efficacy of its products. Baudax Bio Inc. collaborates closely with pharmaceutical companies, clinics, and research facilities to accelerate the development of new products and maintain market leadership in the field of pain relief. Overall, Baudax Bio Inc.'s business model is structured at a high level and emphasizes innovation and pioneering spirit in the field of pain relief. The wide range of products and categories make the company a significant player in the market and a guarantee for growth and success in the future.

odotettu liikevaihto Baudax Bio on 33,66 M USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.

odotettu voitto Baudax Bio on −327 560,75 USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.

P/E-suhdetta ei voida laskea Baudax Bio:lle tällä hetkellä.

P/S-suhdetta ei voida laskea Baudax Bio:lle tällä hetkellä.

Baudax Bio:n Eulpool-laatuscore on 3/10.

Baudax Bio:n ISIN on US07160F1075. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

Baudax Bio:n WKN on A2PU9U. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

Baudax Bio:n ticker on BXRX. Tämä pörssinoteeraus käytetään Baudax Bio-osakkeiden kauppaan pörssissä.